Filters
A cross-sectional study by the German Migraine and Headache Society reports a lower use of analgesics among physically active women prone to headaches vs physically inactive counterparts.
The novel once-daily sustained-release (SR) pregabalin formulation is safe and as good as the twice-daily immediate-release (IR) formulation at reducing peripheral neuropathic pain, according to the results of a phase III trial.
The use of magnesium oxide either alone or in combination with riboflavin may help prevent episodic migraines during pregnancy, according to a study presented at SMFM 2022.
An artificially intelligent olfactory system has the potential to detect Parkinson’s disease through the odour profile of sebum, as shown in a study.
Percutaneous transforaminal endoscopic discectomy (PTED) is as effective as open microdiscectomy in alleviating leg pain caused by lumbar disc herniation, results of a trial have shown. PTED can thus be considered as an alternative to open microdiscectomy in the treatment of sciatica.
New drug applications approved by US FDA as of 16-28 February 2022 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
The use of wearable devices is feasible for the automated seizure detection in the home environment, leading to better care outcomes, such as fewer seizure-related injuries and more accurate seizure diaries, according to a recent study.
Eptinezumab reduces migraine days for both episodic and chronic migraine patients, and the drug’s efficacy and safety profile are independent of age, sex, and body mass index, as shown in a study.
Quantitative sensory testing (QST) yields reliable measures of pain threshold and tolerance, reveals a new study. However, measurements for sensitivity to changes in temperature are less reliable and may be affected by time and other contextual factors.
Patients with chronic obstructive pulmonary disease (COPD) and allied conditions are at heightened risk of stroke, but treatment with mucolytic agents and the combination of inhaled corticosteroids (ICS) plus long-acting β2-agonists (LABA) may protect against the risk, as shown in a study.
